Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis

Jacopo Garlasco, Mario Cesare Nurchis, Valerio Bordino, Martina Sapienza, Gerardo Altamura, Gianfranco Damiani and Maria Michela Gianino
Additional contact information
Jacopo Garlasco: Department of Public Health Sciences and Paediatrics, University of Turin, 10126 Turin, Italy
Mario Cesare Nurchis: Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A, Gemelli IRCCS, 00168 Rome, Italy
Valerio Bordino: Department of Public Health Sciences and Paediatrics, University of Turin, 10126 Turin, Italy
Martina Sapienza: Department of Health Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
Gerardo Altamura: Department of Health Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
Gianfranco Damiani: Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A, Gemelli IRCCS, 00168 Rome, Italy
Maria Michela Gianino: Department of Public Health Sciences and Paediatrics, University of Turin, 10126 Turin, Italy

IJERPH, 2022, vol. 19, issue 8, 1-17

Abstract: Cancers currently represent a leading cause of morbidity and mortality, and precisely estimating their burden is crucial for evidence-based decision-making. This study aimed at understanding the average costs of cancer-related disability-adjusted life years (DALYs) and highlighting possible differences in economic estimates obtained with diverse approaches. We searched four scientific databases to identify all the primary literature simultaneously investigating cancer-related costs and DALYs. In view of the different methodologies, studies were divided into two groups: those estimating costs starting from DALYs, and those independently performing cost and DALY analyses. The latter were pooled to compute costs per disease-related DALY: meta-analytic syntheses were performed for total costs and indirect costs, and in relation to the corresponding gross domestic product (GDP) per capita. The quality of included studies was assessed through the Quality of Health Economic Studies instrument. Seven studies were selected. Total and indirect pooled costs per DALY were, respectively, USD 9150 (95% CI: 5560–15,050) and USD 3890 (95% CI: 2570–5880). Moreover, the cost per cancer-related DALY has been found to be, on average, 32% (95% CI: 24–42%) of the corresponding countries’ GDP per capita. Costs calculated a priori from DALYs may lead to results widely different from those obtained after data retrieval and model building. Further research is needed to better estimate the economic burden of cancer in terms of costs and DALYs.

Keywords: cost-per-DALY ratio; health policy; cancer; chronic diseases; systematic review (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/8/4862/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/8/4862/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:8:p:4862-:d:795627

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().